Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

7.795 -0.105 (-1.33%)
Streaming Delayed Price Updated: 12:32 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,013
Open 7.800
Bid (Size) 7.650 (1,000)
Ask (Size) 7.940 (100)
Prev. Close 7.900
Today's Range 7.795 - 7.950
52wk Range 6.465 - 12.74
Shares Outstanding 51,827,910
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-17.1%
-17.1%
1 Month
+0.8%
+0.8%
3 Month
-0.6%
-0.6%
6 Month
-24.0%
-24.0%
1 Year
-20.5%
-20.5%

More News

Read More
News headline image
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued ↗
Via Stocktwits
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
Via Finterra
Topics Lawsuit
News headline image
Xilio Therapeutics Announces Pricing of Underwritten Offering
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Revenue Jumps 246 Percent in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Xilio Therapeutics, Inc. - Common Stock publicly traded?
Yes, Xilio Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Xilio Therapeutics, Inc. - Common Stock trade on?
Xilio Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Xilio Therapeutics, Inc. - Common Stock?
The ticker symbol for Xilio Therapeutics, Inc. - Common Stock is XLO on the Nasdaq Stock Market
What is the current price of Xilio Therapeutics, Inc. - Common Stock?
The current price of Xilio Therapeutics, Inc. - Common Stock is 7.795
When was Xilio Therapeutics, Inc. - Common Stock last traded?
The last trade of Xilio Therapeutics, Inc. - Common Stock was at 06/10/26 12:32 PM ET
What is the market capitalization of Xilio Therapeutics, Inc. - Common Stock?
The market capitalization of Xilio Therapeutics, Inc. - Common Stock is 404.00M
How many shares of Xilio Therapeutics, Inc. - Common Stock are outstanding?
Xilio Therapeutics, Inc. - Common Stock has 404M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.